Document Classification

Section Type: RESULTS

Text: Women taking raloxifene were less likely to develop osteoporosis (relative risk [RR] for raloxifene v placebo : 0. 13 ; 95 % CI : 0. 00, 0. 37 ; P = 0. 001) or osteopenia (RR : 0. 23 ; 95 % CI : 0. 00, 0. 81 ; P = 0. 038) at the lumbar spine and were more likely to convert to normal BMD status at the lumbar spine (RR : 4. 01 ; 95 % CI : 1. 34, 11. 23 ; P = 0. 043) and total hip (RR : 3. 92 ; 95 % CI : 1. 12, 14. 27 ; P = 0. 011) at 5 years, compared with the case of placebo.